Jump to content

CureVac COVID-19 vaccine

From Simple English Wikipedia, the free encyclopedia

The CureVac COVID-19 vaccine was a COVID-19 vaccine candidate created by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI).[1]

The vaccine showed bad results in its Phase III trials with only 47% effective.[2] The vaccine was never sold.[3]

References

[change | change source]
  1. ↑ "CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide". CureVac (Press release). 15 March 2020. Archived from the original on 8 March 2021. Retrieved 17 February 2021.
  2. ↑ Burger, Ludwig (2021-06-16). "CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy". Reuters. Retrieved 2021-06-17.
  3. ↑ Szymanska Z, Burger L (2021-10-12). "CureVac drops COVID-19 vaccine, pins hope on next-generation shots". Reuters. Retrieved 2021-12-30.


Retrieved from "https://simple.wikipedia.org/w/index.php?title=CureVac_COVID-19_vaccine&oldid=8961219"